Please Wait
Applying Filters...
menu
    • menu
    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    IKF/Pharmasynthese have been with fine chemicals market and APIs performance for more than 40 years.

    Virtual Booth

    Contact Supplier

    Cosma S.p.A., part of CFM Group with AMSA & Clarochem, provides global pharma & veterinary health with 300+ tons of FDA-approved APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Soquelitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 185,288Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Corvus Pharma Confirms Positive Phase 1 Trial Data
    Corvus Pharma Confirms Positive Phase 1 Trial Data

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221554/0/en/Corvus-Pharmaceuticals-Announces-Positive-Data-from-Cohort-4-Confirming-Results-for-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Corvus Pharma To Report Cohort 4 Results Of Soquelitinib Trial
    Corvus Pharma To Report Cohort 4 Results Of Soquelitinib Trial

    16 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/16/3220545/0/en/Corvus-Pharmaceuticals-to-Announce-Results-from-Cohort-4-of-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis.html

    GLOBENEWSWIRE
    16 Jan 2026
    Share Share
    Corvus Pharma To Release Cohort 4 Results Of Soquelitinib Trial
    Corvus Pharma To Release Cohort 4 Results Of Soquelitinib Trial

    05 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/05/3212781/0/en/Corvus-Pharmaceuticals-Confirms-Plans-to-Announce-Results-from-Cohort-4-of-Placebo-Controlled-Phase-1-Clinical-Trial-of-Soquelitinib-for-Atopic-Dermatitis-in-January-2026-Following.html

    GLOBENEWSWIRE
    05 Jan 2026
    Share Share
    Corvus Pharma Unveils P1/1b Soquelitinib Data in T-Cell Lymphoma
    Corvus Pharma Unveils P1/1b Soquelitinib Data in T-Cell Lymphoma

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201702/0/en/Corvus-Pharmaceuticals-Presents-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Corvus Pharma To Unveil Soquelitinib Phase 1/1B T Cell Lymphoma
    Corvus Pharma To Unveil Soquelitinib Phase 1/1B T Cell Lymphoma

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/03/3179394/0/en/Corvus-Pharmaceuticals-to-Present-Final-Data-from-Soquelitinib-Phase-1-1b-T-Cell-Lymphoma-Trial-at-the-67th-American-Society-of-Hematology-Annual-Meeting-Exposition.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    Corvus Pharma' Business Update & Q2 2025 Financial Results
    Corvus Pharma' Business Update & Q2 2025 Financial Results

    31 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/31/3125360/0/en/Corvus-Pharmaceuticals-to-Provide-Business-Update-and-Second-Quarter-2025-Financial-Results-on-August-7-2025.html

    GLOBENEWSWIRE
    31 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.